Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
Walter
Roland B
RB
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-373, Seattle, WA 98109-1024, USA. rwalter@fhcrc.org
Raden
Brian W
BW
Kamikura
Darren M
DM
Cooper
Jonathan A
JA
Bernstein
Irwin D
ID
D000617:Aminoglycosides / Q000633:toxicity*; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000235:genetics* / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000235:genetics* / Q000378:metabolism; D001665:Binding Sites; D001752:Blast Crisis; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D005434:Flow Cytometry; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology; D021381:Protein Transport; D063268:Sialic Acid Binding Ig-like Lectin 3; D014443:Tyrosine
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D014443:Tyrosine; D000079982:Gemtuzumab